Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 2, 2016, Pages 294-305

  Reitter, E M ^a   Kaider, A ^a   Ay, C ^a   Quehenberger, P ^a   Marosi, C ^a   Zielinski, C ^a   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarkers; Cancer; D dimer; Hemostasis; Survival; Venous thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; PADGEM PROTEIN; PLATINUM COMPLEX; THROMBIN; ANTINEOPLASTIC AGENT; F8 PROTEIN, HUMAN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE FRAGMENT; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2; SELP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; COLORECTAL CANCER; DEATH; DISTANT METASTASIS; FEMALE; HEMOSTASIS; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; VERY ELDERLY; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOSTASIS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; P-SELECTIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTHROMBIN; RISK ASSESSMENT; RISK FACTORS; THROMBIN; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84958158874     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13218     Document Type: Article

References (41)

1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
2. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465-73.
3. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012; 32: 115-25.
4. Falanga A, Marchetti M. Anticancer treatment and thrombosis. Thromb Res 2012; 129: 353-9.
5. Rosovsky R, Lee AY. Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy? Hematology Am Soc Hematol Educ Program 2010; 2010: 150-2.
6. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
7. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-9.
8. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-59.
9. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22: 49-60.
10. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 2009; 27: 4821-6.
11. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-82.
12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-7.
13. Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126: 113-18.
14. Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C, Zielinski C, Pabinger I. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29: 2176-81.
15. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-103.
16. Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y, Zhang J, Luo Y, Zhang L, Zheng S, Zhou Q, Li H, Liu Y, Qu X. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer 2012; 12: 330-8.
17. Qiu J, Yu Y, Fu Y, Ye F, Xie X, Lu W. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 2012; 38: 651-7.
18. Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013; 109: 1123-9.
19. Tiedje V, Dunkler D, Ay C, Horvath B, Quehenberger P, Pabinger M, Zielinski C, Pabinger I, Mannhalter C. The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost 2011; 106: 908-13.
20. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-90.
21. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
22. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-91.
23. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2: 1760-5.
24. Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303.
25. Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-93.
26. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179-85.
27. Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, Panzer S, Quehenberger P, Pabinger I, Mannhalter C. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007; 53: 1235-43.
28. Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17: 237-46.
29. Dickmann B, Ahlbrecht J, Ay C, Dunkler D, Thaler J, Scheithauer W, Quehenberger P, Zielinski C, Pabinger I. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98: 1309-14.
30. Inal T, Anar C, Polat G, Unsal I, Halilcolar H. The prognostic value of D-dimer in lung cancer. Clin Respir J 2014; 9: 305-13.
31. von Tempelhoff GF, Niemann F, Schneider DM, Kirkpatrick CJ, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998; 90: 73-82.
32. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, Fey MF. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002; 88: 745-9.
33. Cermak J, Feyereislova A, Horejsi J. Circulating immune complexes in acute leukemia. Neoplasma 1989; 36: 21-7.
34. Yasuda K, Sunami E, Kawai K, Nagawa H, Kitayama J. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 2012; 43: 236-43.
35. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santoro N, Marchetti M, De Mattia D, Falanga A. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol 2010; 85: 325-30.
36. Falanga A, Toma S, Marchetti M, Palumbo R, Raffo P, Consonni R, Marziali S, Dastoli G, Barbui T. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer. Am J Hematol 2002; 70: 9-15.
37. Oberhoff C, Szymeczek J, Hoffmann O, Winkler UH, Kaiser S, Schindler AE. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat 1998; 50: 73-81.
38. Stender MT, Larsen TB, Lundbye-Christensen S, Yilmaz MK, Thorlacius-Ussing O. Haemostatis activity in rectal cancer patients exposed to preoperative radiotherapy: a clinical prospective cohort study. Blood Coagul Fibrinolysis 2009; 20: 276-82.
39. van Marion AM, Auwerda JJ, Lisman T, Sonneveld P, de Maat MP, Lokhorst HM, Leebeek FW. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32: 1078-84.
40. Stender MT, Frokjaer JB, Larsen TB, Lundbye-Christensen S, Thorlacius-Ussing O. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 2009; 52: 446-51.
41. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-64.